Ms. Petrillo’s practice is devoted to intellectual property law and, more specifically, to patent related issues, including the development, management and enforcement of worldwide patent portfolios. Ms. Petrillo has extensive experience in counseling pharmaceutical, biotechnology, chemical and food science companies, including Fortune 500 companies as well as start-up and emerging growth companies, universities, and venture capital firms. She works closely with her clients to protect their commercially important products and achieve their business objectives while helping them avoid infringement of competitors' patents.
She frequently prepares opinions relating to infringement and validity of pharmaceuticals, biopharmaceuticals, vaccines, and formulations, and advises her clients with respect to freedom to operate involving products with multi billion dollar annual sales. She has extensive experience in preparing legal opinions to support Paragraph IV certifications for Abbreviated New Drug Applications (ANDA) under the Hatch-Waxman Act. Ms. Petrillo also evaluates intellectual property portfolios in connection with venture capital and private equity financings, acquisitions and joint development initiatives by her clients. Ms. Petrillo has handled re-examination and reissue matters, and regularly works with foreign counsel in developing worldwide intellectual property protection and devising strategies for patent oppositions in foreign jurisdictions. Ms. Petrillo has also acted as in-house patent counsel for clients and has negotiated their license agreements and drafted other technology related agreements.
Ms. Petrillo has worked in a wide range of technologies including diagnostic assays for detecting various disease states, polymeric formulations for reducing potassium or sodium levels in vivo, small organic molecules for treating pain, cancer and other indications, contrast agents for use in MRI and optimal imaging, NF-KB inhibitors, herbicide formulations, oil processing methods and enhanced oil compositions, solid oxide fuel cells, carbon capture technologies, protein purification processes, biocides, single crystal silicon manufacture, biofuel cells, immobilized enzyme materials, transgenic plants, assays for measuring ribosomal translational activity in normal, stressed, or dying cells, microalgae for biofuels, bioactive conductive polymers, high throughput screening methods, engineered tissues for use as vasculature or cartilage replacement, and recombinant proteins for use as blood substitutes or in treating anemia or chronic heart failure.
United States Patent and Trademark Office